Celestino P Lombardi
Overview
Explore the profile of Celestino P Lombardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garber J, Papini E, Frasoldati A, Lupo M, Harrell R, Parangi S, et al.
Endocr Metab Immune Disord Drug Targets
. 2022 Jan;
21(11):2104-2115.
PMID: 35026973
Objective: The first edition of the American Association of Clinical Endocrinology/American College of Endocrinology/Associazione Medici Endocrinologi Guidelines for the Diagnosis and Management of Thyroid Nodules was published in 2006 and...
2.
Garber J, Papini E, Frasoldati A, Lupo M, Harrell R, Parangi S, et al.
Endocr Pract
. 2021 Jun;
27(7):649-660.
PMID: 34090820
Objective: The first edition of the American Association of Clinical Endocrinology/American College of Endocrinology/Associazione Medici Endocrinologi Guidelines for the Diagnosis and Management of Thyroid Nodules was published in 2006 and...
3.
Raffaelli M, De Crea C, Sessa L, Tempera S, Belluzzi A, Lombardi C, et al.
Endocrine
. 2018 Oct;
63(2):310-315.
PMID: 30341706
Purpose: We aimed to evaluate risk factors for local recurrence following lateral neck dissection (LND) for papillary thyroid carcinoma (PTC). Methods: Two hundred and nine patients who underwent therapeutic primary...
4.
Raffaelli M, De Crea C, DAmato G, Gallucci P, Lombardi C, Bellantone R
Surgery
. 2016 Nov;
161(1):264-271.
PMID: 27865591
Background: We compared operative and metabolic outcomes in patients with subclinical Cushing syndrome and Cushing syndrome caused by unilateral adrenal lesion, aiming to clarify the role of glucocorticoid replacement treatment...
5.
Raffaelli M, De Crea C, Sessa L, Fadda G, Bellantone C, Lombardi C
Ann Surg Oncol
. 2015 Feb;
22(7):2302-8.
PMID: 25652046
Background: Ipsilateral central compartment node dissection (IpsiCCD) can reduce the morbidity of prophylactic bilateral central compartment node dissection (BilCCD) in papillary thyroid carcinoma (PTC) but it carries the risk of...
6.
Bellantone R, Lombardi C, Raffaelli M
Curr Opin Oncol
. 2014 Nov;
27(1):44-9.
PMID: 25390555
Purpose Of Review: The role of endoscopic adrenalectomy for adrenocortical carcinoma is the most controversial and debated points in adrenal surgery. We reviewed the most recent literature on this topic....
7.
Rossi E, Martini M, Capodimonti S, Straccia P, Revelli L, Lombardi C, et al.
Appl Immunohistochem Mol Morphol
. 2014 Jul;
23(3):196-201.
PMID: 24992171
Well-differentiated carcinoma (WDC) accounts for up to 90% of all thyroid cancers. The presence of a minor poorly differentiated (PD) component (mainly insular pattern) might represent an additional critical parameter...
8.
De Crea C, Raffaelli M, Milano V, Carrozza C, Zuppi C, Bellantone R, et al.
World J Surg
. 2013 Nov;
38(3):568-75.
PMID: 24253105
Background: The extension of the compartment-oriented neck dissection at primary surgery in medullary thyroid carcinoma (MTC) is controversial. Because a <50 % decrease in intraoperative calcitonin levels (IO-CT) after total...
9.
Raffaelli M, Brunaud L, De Crea C, Hoche G, Oragano L, Bresler L, et al.
World J Surg
. 2013 Nov;
38(3):709-15.
PMID: 24240671
Background: Synchronous endoscopic bilateral adrenalectomy (BilA) can effectively provide definitive cure of hypercortisolism in ACTH-dependent Cushing's syndrome and in primary adrenal bilateral disease. We compared three different approaches for BilA:...
10.
Rossi E, Straccia P, Palumbo M, Stigliano E, Revelli L, Lombardi C, et al.
Appl Immunohistochem Mol Morphol
. 2012 Dec;
21(3):237-41.
PMID: 23235344
Aim: Thyroid cancer represents the first endocrine malignant neoplasm, accounting for 1% of human malignancy. The majority of which are well-differentiated cancer representing up to 90% of thyroid cancer and...